<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/228553-controlled-release-and-taste-masking-pharmaceutical-composition by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:09:12 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 228553:&quot;CONTROLLED RELEASE AND TASTE-MASKING PHARMACEUTICAL COMPOSITION&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;CONTROLLED RELEASE AND TASTE-MASKING PHARMACEUTICAL COMPOSITION&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Controlled release and taste-masking pharmaceutical composition containing an active ingredient ranges from 5 to 95%, containing characterized in that: i) a matrix consisting of lipophilic compounds with melting point lower than 90 °C wherein the active ingredient is partially inglobated consisting of C6-C20 alcohols or C8-C20 fatty acids or easters of fatty acids with glycerol or sorbitol or other polyaclcohols with carbon atom chain not higher than six and the said lipophilic matrix compounds selected from unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, mono-, di- or triglycerids of fatty acids, the polyethoxylated derivatives thereof, waxes, cholesterol derivatives; ii) an amphiphilic matrix are polar lipids of type I or II (lecithin, phosphatidylcholine, phosphatidyl-ethanolamine), ceramides, glycol alkyl ethers, esters of fatty acids with polyethylene glycols or diethylene glycois; iii) an outer hydrophilic matrix consisting of hydrogels in which the lipophilic matrix and the amphiphilic matrix are dispersed wherein hydrophilic matrix consists of compounds selected from acrylic or methacrylic acid polymers pr copolymers, cellulose, polysaccharides, dextrins, pectins, starches and derivatives, alginic acid, natural or synthetic gums, polyalcohols; iv) optionally a gastro-resistant outer coating of the kind as herein described; and other excipients. 21</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> The presence of the amphiphilic matrix inside the lipophilic matrix inert allows to prevent any unevenness of the release profile of the active ingredient. The surfactants present in the amphiphilic portion promote wettability of the porous canaliculuses which cross the inert matrix preventing or reducing resistance to penetration of the solvent inside the inert matrix.<br>
To obtain taste masking tablets, the components of the hydrophilic matrix are carefully selected to minimize the active substance release time through penetration accelerated by the canalization induced by the hydrophilic compound.<br>
STATEMENT OF THE INVENTION<br>
In accordance with the present invention it is associated to Controlled release and taste-masking pharmaceutical compositions containing an active ingredient ranges from 5 to 95%, containing characterized in that: i) a matrix consisting of lipophilic compounds with melting point lower than 90 °C wherein the active ingredient is partially inglobated consisting of C6-C20 alcohols or C8-C20 fatty acids or easters of fatty acids with glycerol or sorbitol or other polyaclcohols with carbon atom chain not higher than six and the said lipophilic matrix compounds selected from unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, mono-, di- or triglycerids of fatty acids, the polyethoxylated derivatives thereof, waxes, cholesterol derivatives; ii) an amphiphilic matrix are polar lipids of type I or II (lecithin, phosphatidylcholine, phosphatidyl-ethanolamine), ceramides, glycol alkyl ethers, esters of fatty acids with polyethylene glycols or diethylene glycols; iii) an outer hydrophilic matrix consisting of hydrogels in which the lipophilic matrix and the amphiphilic matrix are dispersed wherein hydrophilic matrix consists of compounds selected from acrylic or methacrylic acid polymers pr copolymers, cellulose, polysaccharides, dextrins, pectins, starches and derivatives, alginic acid, natural or synthetic gums, polyalcohols; iv) optionally a gastro-resistant outer coating of the kind as herein described; and other excipients.<br>
The following Examples illustrate the invention in greater detail.<br>
EXAMPLE 1 500 g of 5-aminosalicylic acid and 20 g of octylonium bromide are mixed with 10 g of soy lecithin dissolved in 50 g of a water: ethyl alcohol 1: 3 mixture at about 50°C.<br>
After homogenization and drying, the granules of the resulting matrix are treated in a kneader with 20 g of carnauba wax and 50 g of stearic acid, heating until homogeneous dispersion, then cold-extruded into small granules. The inert matrix granules are loaded into a mixer in which 30 g of carbopol 971 P and 65 g of hydroxypropyl methylcellulose are sequentially added. After a first mixing step for homogeneously dispersing the powders, 60 g of microcrystalline cellulose and 5 g of magnesium stearate are added. After mixing, the final mixture is tabletted to unitary weight of 760 mg/tablet. The resulting tablets are film-coated with cellulose acetophthalate or polymethacrylates and a plasticizer to provide gastric resistance and prevent the early release of product in the stomach.<br>
The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 30%, after 180 minutes no more than 60%, after 5 hours no more than 80%.<br><br>
EXAMPLE 2<br>
50 g of diethylene glycol monoethyl ether are homogeneously distributed on 500 g of microcrystalline cellulose; then 100 g of Budesonide are added, mixing to complete homogenization. This mix is further added with 400 g of Budesonide, then dispersed in a blender containing 100 g of carnauba wax and 100 g of stearic acid preheated at a temperature of 60°C. After kneading for 5 minutes, the mixture is cooled to room temperature and extruded in granules of size below 1 mm.<br>
A suitable mixer is loaded with the matrix granules prepared as above and the following amounts of hydrophilic excipients: 1500 g of hydroxypropyl methylcellulose and 500 g of policarbophil.<br>
The components are mixed until homogeneous dispersion of the matrices, then added with 2450 g of microcrystalline cellulose, 400 g of lactose, 100 g of colloidal silica and 50 g of magnesium stearate. After further 5 minute mixing, the mix is tabletted to unitary weight of 250 mg/tablet.<br>
EXAMPLE 3<br>
850 g of metformin are dispersed in a granulator/kneader with 35 g of diethylene glycol monoethyl ether previously melted with 100 g of stearic acid and 55 g of carnauba wax. The system is heated to carry out the granulation of the active ingredient in the inert matrTx. The resulting 1040 g of formulation are added with 110 g of hydroxypropyl methylcellulose and 20 g of magnesium stearate.<br>
The final mixture is tabletted to unitary weight of 1170 mg/tablet equivalent to 850 mg of active ingredient.<br>
The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 35%, after 180 minutes no more than<br><br>
60%, after 5 hours no more than 80%.<br>
EXAMPLE 4<br>
120 g of octylonium bromide are dispersed in a granulator/kneader with 30 g of stearic acid and 15 g of beeswax in which 10 g of diethylene glycol monoethylene had previously been melted.<br>
The system is heated to carry out the granulation of the active ingredient in the inert matrix. The resulting 10 g of formulation are added with 5 g of hydroxypropyl methylcellulose and 5 g of policarbophyl, 2 g of magnesium stearate and 3 g of microcrystalline cellulose.<br>
The final mixture is tabletted to unitary weight of 200 mg/tablet equivalent to 120 mg of active ingredient.<br>
The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 25%; after 180 minutes no more than 50%; after 5 hours no more than 70%.<br>
EXAMPLE 5<br>
12 g of diethylene glycol monoethyl ether are loaded on 6 g of microcrystalline cellulose and 6 grams of calcium carbonate, then 100 g of Gabapentin are added and the mixture is homogenized. After that, 800 g of Gabapentin are added which are dispersed in a granulator/kneader with 4.5 g of white wax and 5 g of stearic acid. The system is heated to carry out the granulation of the active ingredient in the inert matrix. The resulting 916.5 g of formulation are added with 39.5 g of hydroxypropyl methylcellulose, 10 g of alginic acid, 11 g of magnesium stearate and 6 g of syloid. The final mixture is tabletted to unitary weight of 1000 mg/tablet equivalent to 900 mg of active ingredient.<br>
EXAMPLE   6<br>
50 g (25 g) of carbidopa and 200 g (100 g) of levodopa<br><br>
are dispersed in a granulator/kneader with 60 g (30 g) of<br>
stearic acid and 30 g (15 g) of yellow wax, in which 10 (5) g of diethylene glycol monoethyl ether had previously been melted.<br>
The system is heated to carry out the granulation of the active ingredient in the inert matrix. The resulting 340 g (170 g) of formulation are added with 20 g (10 g) of hydroxypropyl methylcellulose, 10 g (5 g) of xantangum, 16 g (8 g) of microcrystalline cellulose, 4 g (2 g) of magnesium stearate.<br>
The final mixture is tabletted to unitary weight of 400 (200) mg/tablet equivalent to 50(25) mg of carbidopa and 200 (100) mg di levodopa.<br>
EXAMPLE 7<br>
4 g of Nimesulide are solubilised in 50 g of diethylene glycol monoethyl ether, then 100 g of microcrystalline cellulose are added to obtain a homogeneous mixture.<br>
The resulting mixture is added in a granulator/kneader with 196 g of Nimesulide, 50 g of stearic acid and 25 g of carnauba wax. The system is heated to carry out the granulation of the active ingredient in the inert and amphiphilic matrix system.<br>
425 g of the resulting granulate are added with 60 g of hydroxypropyl methylcellulose, 5 g of policarbophil" and 10 g of magnesium stearate.<br>
The final mixture is tabletted to unitary weight of 500 mg/tablet equivalent to 200 mg of active ingredient.<br>
The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 1 hour no more than 25%, after 2 hours no more than 40%, after 4 hours no more than 60%, after 8 hours no more than 90%.<br><br>
EXAMPLE 8<br>
500 g of propionyl carnitine are dispersed in a granulator/kneader with 90 g of stearic acid and 40 g of carnauba wax, in which 20 g of diethylene glycol monoethyl ether had previously been melted. The system is heated to carry out the granulation of the active ingredient in the inert/amphiphilic matrix. The resulting 650 g of formulation are added with 60 g of hydroxypropyl methylcellulose and 10 g of magnesium stearate.<br>
The final mixture is tabletted to unitary weight of 720 mg/tablet equivalent to 500 mg of active ingredient.<br>
The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 40%, after 180 minutes no more than 60%, after 4 hours no more than 80%, after 8 hours no more than 90%.<br>
••,<br>
EXAMPLE 9<br>
One kg of Nimesulide is placed in a high rate granulator, pre-heated to about 70°, together with 200 g of cetyl alcohol and 25 g of glycerol palmitostearate; the mixture is kneaded for about 15 minutes and stirred while decreasing temperature to about 30°C. The resulting inert matrix is added, keeping stirring and kneading during cooling, with 50 g of soy lecithin and 50 g of ethylene glycol monoethyl ether. The granulate is extruded through a metallic screen of suitable size and mixed with 50 g of hydroxypropyl methylcellulose, 1320 kg of maltodextrins, 2 kg of lactose-cellulose mixture, 50 g of colloidal silica, 40 g of aspartame, 150 g of citric acid, 75 g of flavour and 65 g of magnesium stearate. The final mixture is tabletted to unitary weight of about 500 mg, having hardness suitable for being dissolved in the mouth and a pleasant taste.<br><br>
EXAMPLE 10<br>
Operating as in the preceding example, chewable tablets are prepared replacing dextrin with mannitol and the lactose-cellulose mixture with xylitol. The resulting tablets ahve pleasant taste and give upon chewing a sensation of freshness enhancing the flavour. EXAMPLE 11<br>
Operating as described in example 9, but with the following components:<br>
active ingredient: ibuprofen	mg 100<br>
lipophilic/inert matrix component:<br>
cetyl alcohol	mg  15<br>
amphiphilic matrix component:<br>
soy lecithin	mg   8<br>
hydrophilic matrix components: mannitol  mg 167<br>
maltodextrins	mg 150<br>
methylhydroxypropylcellulose	mg  30<br>
adjuvants: aspartame	mg  15<br>
flavour	mg  5<br>
colloidal silica	mg   5<br>
magnesium stearate	mg  5<br>
500 mg unitary weight tablets are obtained, which<br>
undergo progressive erosion upon buccal administration, and<br>
effectively mask the bitter, irritating taste of the active<br>
ingredient.	"<br>
EXAMPLE 12<br>
Operating as described in example 9, but with the following components:<br>
active ingredient: diclofenac sodium        mg  25 lipophilic/inert matrix component:<br>
cetyl alcohol	mg  5<br>
glycerol palmitostearate	mg   5<br>
amphiphilic matrix component:<br>
soy lecithin	mg   7<br><br>
17 hydrophilic matrix components: xylitol      mg 168<br>
maltodextrins	mg 150<br>
hydroxypropylmethylcellulose	mg  20<br>
adjuvants: aspartame	mg  5<br>
flavour	mg   5<br>
colloidal silica	mg   5<br>
magnesium stearate	mg  5<br>
400 mg unitary weight tablets are	obtained,  which<br>
undergo progressive erosion upon buccal administration, and<br>
effectively  mask  the  irritating  taste	of  the  active<br>
ingredient.<br>
EXAMPLE 13<br>
Operating as described in example 9,  but with the<br>
following components:<br>
active ingredient: chlorhexidine	mg 2, 5<br>
lipophilic/inert matrix component:<br>
cetyl alcohol	mg 0.5<br>
-•.<br>
glycerol palmitostearate	mg 0 . 5<br>
amphiphilic matrix component:<br>
diethylene glycol monoethyl ether	mg 0.3<br>
hydrophilic matrix components: xylitol	mg 38<br>
maltodextrins	mg 96<br>
hydroxypropyl methylcellulose	mg 10<br>
adjuvants: aspartame	mg  3<br>
flavour	mg   5<br>
colloidal silica	mg  2<br>
magnesium stearate	mg   2<br>
150 mg unitary weight tablets are	obtained,  which<br>
undergo progressive erosion upon buccal administration, and<br>
effectively  mask  the  irritating  taste	of  the  active<br>
ingredient.<br>
EXAMPLE 14<br>
One  Kg  of  Nimesulide  is  placed  in  a high  rate granulator, pre-heated to about 70°, together with g 125 of<br><br>
cetyl alcohol: the mixture is kneaded for about 15 minutes<br>
and stirred while decreasing temperature to about 30°C, then added with g 30 of lecithin. The resulting matrix is then extruded through a metallic screen of suitable size and mixed with 2.415 kg of lactose, 1.0 kg of maltodextrins, 50 g of hydroxypropyl methylcellulose, 50 g of colloidal silica, 40 g of aspartame, 150 g of citric acid, 75 g of flavour and 65 g of magnesium stearate. The final mixture is tabletted to about 500 mg tablets, having hardness suitable for being dissolved in the mouth and pleasant taste.<br><br><br><br><br><br><br>
We Claim:<br>
1.	Controlled release and taste-masking pharmaceutical compositions containing an<br>
active ingredient ranges from 5 to 95%, containing characterized in that:<br>
a)	a matrix consisting of lipophilic compounds with melting point lower than 90 °C<br>
wherein the active ingredient is partially inglobated consisting of C6-C20<br>
alcohols or C8-C20 fatty acids or easters of fatty acids with glycerol or sorbitol<br>
or other polyaclcohols with carbon atom chain not higher than six and the said<br>
lipophilic matrix    compounds  selected  from  unsaturated  or hydrogenated<br>
alcohols or fatty acids, salts, esters or amides thereof, mono-, di- or triglycerids<br>
of fatty acids,  the  polyethoxylated  derivatives thereof,  waxes,  cholesterol<br>
derivatives;<br>
b)	an    amphiphilic    matrix    are    polar    lipids    of   type    I    or    II    (lecithin,<br>
phosphatidylcholine,    phosphatidyl-ethanolamine),    ceramides,   glycol   alkyl<br>
ethers, esters of fatty acids with polyethylene glycols or diethylene glycols;<br>
c)	an outer hydrophilic matrix consisting of hydrogels in which the lipophilic matrix<br>
and the amphiphilic matrix are dispersed wherein hydrophilic matrix consists of<br>
compounds selected from acrylic or methacrylic acid polymers pr copolymers,<br>
cellulose, polysaccharides, dextrins, pectins, starches and derivatives, alginic<br>
acid, natural or synthetic gums, polyalcohols;<br><br>
d)	optionally a gastro-resistant outer coating of the kind as herein described; and<br>
e)	other excipients.<br><br>
2.	Compositions as claimed in claim 1, in which the gastro-resistant coating consists of<br>
methacrylic acid polymers or cellulose derivatives.<br>
3.	Compositions as claimed in claim 1, in which the active ingredient is wholly contained<br>
in the inert amphiphilic matrix, in the form of pharmaceutical formulations such as<br>
herein described.<br>
4.	Compositions as claimed in claim 1, wherein the active ingredient is dispersed both in<br>
the   hydrophilic  matrix  and   in  the   lipophilic/amphiphilic  matrix,   in  the  form   of<br>
pharmaceutical formulations such as herein described.<br>
5.	Compositions as claimed in claim 1, in which the active ingredient belongs to the<br>
therapeutical  classes of analgesics,  antitussives,   bronchodilators,  antipsychotics,<br>
selective &amp; 2 antagonists, calcium antagonists, antiparkinson drugs, non-steroidal anti-<br>
inflammatory drugs, antihistamines, antidiarrheals and intestinal antiinflammatories,<br><br><br><br>
spasmolytics,    anxiolytics,    oral   antidiabetics,    cathartics,    antiepileptics,    topical antimicrobials.<br>
6.	Compositions as claimed in claim 1, in which the active ingredient is selected from<br>
mesalazine  (5-aminosalicylic  acid),   budesonide,   metformin,   octylonium   bromide,<br>
gabapentin,   carbidopa,   namesulide,   propionylilcarnitine,   isosorbide   mono-   and<br>
dinitrate, naproxen, ibuprofen, ketoprofen, diclofenac, thiaprophenic acid, nimesulide,<br>
chlorhexidine,     benzydamine,     tibezonium     iodide,     cetylpyridinium     chloride,<br>
benzalkonium chloride, sodium fluoride.<br>
7.	Compositions as claimed in the above claims, containing bioadhesive substances.<br>
8.	Compositions  as  claimed  in  the  above  claims,   in  the form  of pharmaceutical<br>
formulation such as herein described in the buccal cavity or in the first portion of the<br>
gastrointestinal tract.<br>
9.	Controlled-release and taste-masking pharmaceutical compositions substantially as<br>
herein described with reference to the foregoing description and the accompanying<br>
examples.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgxNS1kZWxucC0yMDA1LWRlc2NyaXB0aW9uIChjb21wbGV0ZSktMjgtMDgtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2815-delnp-2005-description (complete)-28-08-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDEtMDExMTMtREVMLUFic3RyYWN0LSgyNy0wOC0yMDA4KS5wZGY=" target="_blank" style="word-wrap:break-word;">IN-PCT-2001-01113-DEL-Abstract-(27-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDEtMDExMTMtREVMLUFic3RyYWN0LTE4LTExLTIwMDgucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2001-01113-DEL-Abstract-18-11-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDEtMDExMTMtREVMLUNsYWltcy0oMjctMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2001-01113-DEL-Claims-(27-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDEtMDExMTMtREVMLUNsYWltcy0xOC0xMS0yMDA4LnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2001-01113-DEL-Claims-18-11-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDEtMDExMTMtREVMLUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMjctMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2001-01113-DEL-Correspondence-Others-(27-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDEtMDExMTMtREVMLUNvcnJlc3BvbmRlbmNlLU90aGVycy0xOC0xMS0yMDA4LnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2001-01113-DEL-Correspondence-Others-18-11-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDEtMDExMTMtREVMLURlc2NyaXB0aW9uIChDb21wbGV0ZSktMTgtMTEtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">IN-PCT-2001-01113-DEL-Description (Complete)-18-11-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDEtMDExMTMtREVMLUZvcm0tMS0xOC0xMS0yMDA4LnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2001-01113-DEL-Form-1-18-11-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWZvcm0tMTMucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-form-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWZvcm0tMTgucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDEtMDExMTMtREVMLUZvcm0tMi0xOC0xMS0yMDA4LnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2001-01113-DEL-Form-2-18-11-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLWZvcm0tNi5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-form-6.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLXBjdC0yMTAucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-pct-210.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLXBjdC0zMDYucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-pct-306.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLXBjdC00MDkucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-pct-409.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDEtMDExMTMtZGVsLXBjdC00MTYucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2001-01113-del-pct-416.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="228552-line-pressure-regulating-system-for-an-automatic-transmission.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="228554-method-and-device-for-reducing-a-dataset-consisting-of-process-data-to-be-transmitted.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>228553</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>IN/PCT/2001/01113/DEL</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>13/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>27-Mar-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>05-Feb-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>03-Dec-2001</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>COSMO TECHNOLOGIES LIMITED</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>2, DUNCAIRN TERRACE-BRAY CO. WICKLOW-IRELAND</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>VILLA, ROBERTO</td>
											<td>EDIFICIO VALLARIO, PISO 6°, CALLE 52 Y ECUIRA MENDEZ, PANAMA CITY</td>
										</tr>
										<tr>
											<td>2</td>
											<td>PEDRANI, MASSIMO</td>
											<td>EDIFICIO VALLARIO, PISO 6°, CALLE 52 Y ECUIRA MENDEZ, PANAMA CITY</td>
										</tr>
										<tr>
											<td>3</td>
											<td>AJANI, MAURO</td>
											<td>EDIFICIO VALLARIO, PISO 6°, CALLE 52 Y ECUIRA MENDEZ, PANAMA CITY</td>
										</tr>
										<tr>
											<td>4</td>
											<td>FOSSATI, LORENZO</td>
											<td>EDIFICIO VALLARIO, PISO 6°, CALLE 52 Y ECUIRA MENDEZ, PANAMA CITY</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 9/16</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP00/05356</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2000-06-09</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>MI99A001317</td>
									<td>1999-06-14</td>
								    <td>Italy</td>
								</tr>
								<tr>
									<td>2</td>
									<td>MI2000A000422</td>
									<td>2000-03-03</td>
								    <td>Italy</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/228553-controlled-release-and-taste-masking-pharmaceutical-composition by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:09:13 GMT -->
</html>
